Health-related quality of life as an independent predictor of long-term disability for patients with relapsing-remitting multiple sclerosis

2013 ◽  
Vol 20 (6) ◽  
pp. 907-e79 ◽  
Author(s):  
K. Baumstarck ◽  
J. Pelletier ◽  
H. Butzkueven ◽  
O. Fernández ◽  
P. Flachenecker ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Multiple Sclerosis ◽  
Independent Predictor ◽  
Health Related Quality ◽  
Relapsing Remitting ◽  
Related Quality ◽  
Health Related ◽  
Relapsing Remitting Multiple Sclerosis

scholarly journals Impact of alemtuzumab on health-related quality of life over 6 years in CARE-MS II trial extension patients with relapsing-remitting multiple sclerosis

2019 ◽  
Vol 26 (8) ◽  
pp. 955-963 ◽  
Author(s):  
Rafael Arroyo ◽  
Denise P Bury ◽  
Jennifer D Guo ◽  
David H Margolin ◽  
Maria Melanson ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Multiple Sclerosis ◽  
Health Related Quality ◽  
Sf 36 ◽  
Relapsing Remitting ◽  
Related Quality ◽  
Health Related ◽  
Relapsing Remitting Multiple Sclerosis ◽  
Eq Vas

Background: In CARE-MS II (Comparison of Alemtuzumab and Rebif® Efficacy in Multiple Sclerosis; NCT00548405), alemtuzumab (12 mg/day; baseline: 5 days; 12 months later: 3 days) significantly improved health-related quality of life (HRQL) outcomes versus subcutaneous interferon beta-1a (SC IFNB-1a) in relapsing-remitting multiple sclerosis (RRMS) patients over 2 years. Patients completing CARE-MS II could enter a 4-year extension study (NCT00930553). Objective: The aim of this study is to assess 6-year HRQL outcomes in alemtuzumab-treated CARE-MS II patients, including those with highly active disease (HAD). Methods: During extension, patients could receive additional alemtuzumab for clinical/magnetic resonance imaging (MRI) activity or other disease-modifying therapies per investigator’s discretion. Assessments include Functional Assessment of Multiple Sclerosis (FAMS), 36-Item Short-Form Health Survey (SF-36), and EQ-5D visual analog scale (EQ-VAS). Results: Alemtuzumab-treated patients improved or stabilized all HRQL measures over 6 years with significant improvements from baseline at all time points on EQ-VAS and for up to 5 years on FAMS, SF-36 MCS, and SF-36 PCS. Alemtuzumab-treated patients with HAD showed significant improvements versus baseline at Year 2 on all HRQL measures, and significant improvements versus SC IFNB-1a on SF-36 PCS and EQ-VAS; however, the improvements did not reach the threshold for clinical relevance. Conclusion: Alemtuzumab-treated CARE-MS II patients improved or stabilized HRQL versus baseline over 6 years. This is the first study to show long-term HRQL benefits in patients with HAD.

Sign in / Sign up

Export Citation Format

Share Document